The therapeutic promise of the cancer stem cell concept.

Cancer stem cells (CSCs) are a subpopulation of tumor cells that selectively possess tumor initiation and self-renewal capacity and the ability to give rise to bulk populations of nontumorigenic cancer cell progeny through differentiation. As we discuss here, they have been prospectively identified in several human malignancies, and their relative abundance in clinical cancer specimens has been correlated with malignant disease progression in human patients. Furthermore, recent findings suggest that clinical cancer progression driven by CSCs may contribute to the failure of existing therapies to consistently eradicate malignant tumors. Therefore, CSC-directed therapeutic approaches might represent translationally relevant strategies to improve clinical cancer therapy, in particular for those malignancies that are currently refractory to conventional anticancer agents directed predominantly at tumor bulk populations.

[1]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[2]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[3]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[4]  R. Bajpai,et al.  Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. , 2008, Cancer research.

[5]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[6]  F. Pajonk,et al.  Radiation responses of cancer stem cells , 2009, Journal of cellular biochemistry.

[7]  O. Fodstad,et al.  The Stem Cell‐Associated Antigen CD133 (Prominin‐1) Is a Molecular Therapeutic Target for Metastatic Melanoma , 2008, Stem cells.

[8]  M. Andreeff,et al.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. , 2001, Blood.

[9]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[10]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[11]  R. McLendon,et al.  Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.

[12]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[13]  M. Vemuri,et al.  Regulatory networks in stem cells , 2009 .

[14]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[15]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[16]  J. Griffin,et al.  Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.

[17]  R. Folberg,et al.  Vasculogenic mimicry , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  J. Lotem,et al.  Epigenetics and the plasticity of differentiation in normal and cancer stem cells , 2006, Oncogene.

[19]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[20]  W. R. Bruce,et al.  A Quantitative Assay for the Number of Murine Lymphoma Cells capable of Proliferation in vivo , 1963, Nature.

[21]  D. Scadden,et al.  The stem-cell niche as an entity of action , 2006, Nature.

[22]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[23]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[24]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[25]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[26]  R. Dummer,et al.  Stemming the flood , 2009, Pigment cell & melanoma research.

[27]  A. Hamburger,et al.  Primary bioassay of human tumor stem cells. , 1977, Science.

[28]  W. Farrar,et al.  Cancer stem cells, CD200 and immunoevasion. , 2008, Trends in immunology.

[29]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[30]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[31]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[32]  A. Elliott,et al.  ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome , 2009, Molecular Cancer Research.

[33]  M. Ziman,et al.  Molecular markers of circulating melanoma cells. , 2007, Pigment cell research.

[34]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[35]  G. B. Pierce.  The cancer cell and its control by the embryo. Rous-Whipple Award lecture. , 1983, The American journal of pathology.

[36]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[37]  R. Folberg,et al.  Vasculogenic mimicry , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[38]  M. Frank,et al.  Identification and targeting of cancer stem cells , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[40]  Hans Clevers,et al.  Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.

[41]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.

[43]  E. Hovig,et al.  Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. , 2009, Leukemia research.

[44]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[45]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[46]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[47]  R. Folberg,et al.  Distinguishing fibrovascular septa from vasculogenic mimicry patterns. , 2005, Archives of pathology & laboratory medicine.

[48]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[49]  Frank Pajonk,et al.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.

[50]  J. Folkman.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[51]  Nicolò Riggi,et al.  Identification of cancer stem cells in Ewing's sarcoma. , 2009, Cancer research.

[52]  E. McCulloch,et al.  Mouse myeloma tumor stem cells: a primary cell culture assay. , 1971, Journal of the National Cancer Institute.

[53]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[54]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[55]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[56]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[57]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[58]  M. Hendrix,et al.  Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. , 2004, Journal of the National Cancer Institute.

[59]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[60]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[61]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[62]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[63]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[64]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[65]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[66]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[67]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[69]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[70]  D. Stearns,et al.  Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. , 2006, Cancer research.

[71]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[72]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[73]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[74]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[75]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[76]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[77]  M. Frank,et al.  Solid Tumor Stem Cells – Implications for Cancer Therapy , 2009 .

[78]  M. Carroll,et al.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. , 2007, Blood.

[79]  M. Sayegh,et al.  Immunomodulatory functions of mesenchymal stem cells , 2004, The Lancet.

[80]  P. Kearns,et al.  Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. , 2007, Blood.

[81]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[82]  M. Frank,et al.  ABCB5 gene amplification in human leukemia cells. , 2009, Leukemia research.

[83]  Sean J. Morrison,et al.  Asymmetric and symmetric stem-cell divisions in development and cancer , 2006, Nature.

[84]  S. Chiou,et al.  Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. , 2009, Biochemical and biophysical research communications.

[85]  Megan Sykes,et al.  Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[87]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[88]  D. Olive,et al.  Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. , 2000, Cancer research.

[89]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[90]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[91]  R. Richardson,et al.  Prominin1 marks intestinal stem cells that are susceptible to neoplastic transformation , 2008, Nature.

[92]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[93]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[94]  R. Schwartz,et al.  Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[95]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[96]  J. Sayre,et al.  In vivo imaging, tracking, and targeting of cancer stem cells. , 2009, Journal of the National Cancer Institute.

[97]  E. M. Espreafico,et al.  Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets , 2008, BMC Cancer.

[98]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[99]  C. Pérez-Plasencia,et al.  A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer , 2006, PloS one.

[100]  Pierce Gb.  The cancer cell and its control by the embryo. Rous-Whipple Award lecture. , 1983 .

[101]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[102]  M. Frank,et al.  Antitumor Immunity and Cancer Stem Cells , 2009, Annals of the New York Academy of Sciences.

[103]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[104]  J. Griffin,et al.  Heterogeneity of clonogenic cells in acute myeloblastic leukemia. , 1985, The Journal of clinical investigation.

[105]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[106]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[107]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[108]  M. Raaijmakers,et al.  Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38− cells , 2006, Leukemia.

[109]  K. Anderson,et al.  Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia , 2005, Nature Medicine.

[110]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[111]  D. Elder,et al.  Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. , 1993, The American journal of pathology.

[112]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[113]  A. Bosserhoff,et al.  Functional implication of BMP4 expression on angiogenesis in malignant melanoma , 2006, Oncogene.

[114]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[115]  M. Clarke,et al.  Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy , 2008, PloS one.

[116]  N. Goulden,et al.  Characterization of acute lymphoblastic leukemia progenitor cells. , 2004, Blood.

[117]  M. Frank,et al.  Cancer stem cells and human malignant melanoma , 2007, Pigment Cell & Melanoma Research.

[118]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[119]  Shuping Zhao,et al.  Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.

[120]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[121]  Myriam Alcalay,et al.  Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells , 2009, Nature.

[122]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[123]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[124]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[125]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[126]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[127]  O. Pereira-smith,et al.  The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay. , 2005, Neoplasia.

[128]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[129]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[130]  O. Ringdén,et al.  Immunomodulation by mesenchymal stem cells and clinical experience , 2007, Journal of internal medicine.